Related references
Note: Only part of the references are listed.A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
Charles Butts et al.
CLINICAL LUNG CANCER (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era
Myung-Ju Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases
Tomoya Kawaguchi et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Targeted therapies for non-small cell lung cancer
Wolfram C. M. Dempke et al.
LUNG CANCER (2010)
EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer
Meina Wu et al.
LUNG CANCER (2010)
Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells
S. Bafna et al.
ONCOGENE (2010)
Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
Nicholas Thatcher et al.
ONCOLOGIST (2010)
Evaluation on the incidence, mortality and tendency of lung cancer in China
Wanqing Chen et al.
THORACIC CANCER (2010)
Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801 Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer
Thomas E. Stinchcombe et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status
Sai-Hong Ignatius et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Systemic effects of local radiotherapy
Silvia C. Formenti et al.
LANCET ONCOLOGY (2009)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future
Chih-Hsin Yang
LUNG CANCER (2008)
Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer
R. E. Roses et al.
ONCOGENE (2008)
Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
Katharine A. R. Price et al.
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY (2008)
Treatment of non-small cell lung cancer, stage IIIB - ACCP evidence-based clinical practice guidelines (2nd edition)
Janws R. Jett et al.
CHEST (2007)
L-BLP25: A peptide vaccine strategy in non-small cell lung cancer
Randeep Sangha et al.
CLINICAL CANCER RESEARCH (2007)
A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis
Charles Butts et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Treatment of non-small cell lung cancer-stage IIIA - ACCP evidence-based clinical practice guidelines (2nd edition)
Lary A. Robinson et al.
CHEST (2007)
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
Chih-Hsin Yang et al.
CANCER (2006)
Combined modality therapy for stage III non-small cell lung cancer
Thomas E. Stinchcombe et al.
ONCOLOGIST (2006)
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer
C Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MUC1 as a target antigen for cancer immunotherapy
B Acres et al.
EXPERT REVIEW OF VACCINES (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
DG Pfister et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
AP Meert et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Staging of non-small cell lung cancer: consensus, controversies and challenges
JP van Meerbeeck
LUNG CANCER (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
